Sana Biotechnology (NASDAQ:SANA) Stock Rating Raised to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Sana Biotechnology (NASDAQ:SANA) from a sell rating to a hold rating in a report issued on Saturday,Wall Street Zen reports.

Other equities analysts have also recently issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Sana Biotechnology in a research report on Wednesday, October 21st. Bank of America decreased their target price on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Finally, TD Cowen raised Sana Biotechnology to a “strong-buy” rating in a report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.60.

Sana Biotechnology Stock Up 1.3%

Shares of SANA opened at $2.37 on Friday. The firm has a 50-day moving average price of $2.88 and a 200 day moving average price of $3.35. The firm has a market capitalization of $709.48 million, a PE ratio of -4.47 and a beta of 2.30. Sana Biotechnology has a 52-week low of $2.22 and a 52-week high of $5.49.

Sana Biotechnology (NASDAQ:SANA) last announced its earnings results on Thursday, November 5th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. On average, equities analysts expect that Sana Biotechnology will post -0.72 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Rockefeller Capital Management L.P. increased its position in shares of Sana Biotechnology by 74.3% during the fourth quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock worth $39,000 after acquiring an additional 4,088 shares in the last quarter. Royal Bank of Canada raised its holdings in shares of Sana Biotechnology by 76.8% during the first quarter. Royal Bank of Canada now owns 12,285 shares of the company’s stock worth $35,000 after acquiring an additional 5,338 shares during the period. Swiss National Bank raised its holdings in shares of Sana Biotechnology by 2.0% during the first quarter. Swiss National Bank now owns 342,600 shares of the company’s stock worth $987,000 after acquiring an additional 6,800 shares during the period. Cetera Investment Advisers lifted its position in Sana Biotechnology by 50.2% in the 1st quarter. Cetera Investment Advisers now owns 26,181 shares of the company’s stock valued at $75,000 after acquiring an additional 8,750 shares in the last quarter. Finally, Walleye Capital LLC bought a new stake in Sana Biotechnology in the 2nd quarter valued at $35,000. 88.23% of the stock is owned by institutional investors.

About Sana Biotechnology

Sana Biotechnology, Inc is a clinical-stage biotechnology company focused on developing engineered cell and gene therapies for serious diseases. The company’s approach is designed to create durable treatments by modifying cells outside or inside the body and using them to replace, repair, or supplement damaged or missing biological functions.

Sana is developing proprietary technologies intended to support the delivery and persistence of therapeutic cells. These include platforms for engineering cells to evade immune-system detection, potentially allowing donor-derived cells to be used without extensive immune suppression, as well as methods for delivering genetic instructions directly to targeted tissues.